How does lack of success of rituximab treatment affect your decision to trial anti-CD19 therapies like inebilizumab?

I strongly believe that deeper and broader CD19 theraphy such as inebilizumab, works on a key different target: offering better disease control due to its broader B-cell targeting, as in CD19, plasmablasts, than rituximab, which targets CD20 (mature B cells), leading to more broad b cell depletion,...

Anti-CD19 therapies have a much broader range of action than anti-CD20s on the cascade of pro-B cells to mature plasma cells. It is therefore quite possible that a patient may respond to anti-CD19 treatment if they did not respond to anti-CD20. There may also be more risks with CD 20s, although the ...